687 related articles for article (PubMed ID: 26670557)
1. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction.
Jiang C; Xie C; Lv Y; Li J; Krausz KW; Shi J; Brocker CN; Desai D; Amin SG; Bisson WH; Liu Y; Gavrilova O; Patterson AD; Gonzalez FJ
Nat Commun; 2015 Dec; 6():10166. PubMed ID: 26670557
[TBL] [Abstract][Full Text] [Related]
2. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.
Gonzalez FJ; Jiang C; Patterson AD
Gastroenterology; 2016 Nov; 151(5):845-859. PubMed ID: 27639801
[TBL] [Abstract][Full Text] [Related]
3. An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.
Xie C; Jiang C; Shi J; Gao X; Sun D; Sun L; Wang T; Takahashi S; Anitha M; Krausz KW; Patterson AD; Gonzalez FJ
Diabetes; 2017 Mar; 66(3):613-626. PubMed ID: 28223344
[TBL] [Abstract][Full Text] [Related]
4. Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease.
Gonzalez FJ; Jiang C; Xie C; Patterson AD
Dig Dis; 2017; 35(3):178-184. PubMed ID: 28249275
[TBL] [Abstract][Full Text] [Related]
5. Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice.
Jiang J; Ma Y; Liu Y; Lu D; Gao X; Krausz KW; Desai D; Amin SG; Patterson AD; Gonzalez FJ; Xie C
Hepatol Commun; 2022 Dec; 6(12):3363-3378. PubMed ID: 36196594
[TBL] [Abstract][Full Text] [Related]
6. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism.
Zhang L; Xie C; Nichols RG; Chan SH; Jiang C; Hao R; Smith PB; Cai J; Simons MN; Hatzakis E; Maranas CD; Gonzalez FJ; Patterson AD
mSystems; 2016; 1(5):. PubMed ID: 27822554
[TBL] [Abstract][Full Text] [Related]
7. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.
Ma Y; Huang Y; Yan L; Gao M; Liu D
Pharm Res; 2013 May; 30(5):1447-57. PubMed ID: 23371517
[TBL] [Abstract][Full Text] [Related]
8. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.
Li F; Jiang C; Krausz KW; Li Y; Albert I; Hao H; Fabre KM; Mitchell JB; Patterson AD; Gonzalez FJ
Nat Commun; 2013; 4():2384. PubMed ID: 24064762
[TBL] [Abstract][Full Text] [Related]
9. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
[TBL] [Abstract][Full Text] [Related]
10. Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis.
Wu Q; Sun L; Hu X; Wang X; Xu F; Chen B; Liang X; Xia J; Wang P; Aibara D; Zhang S; Zeng G; Yun C; Yan Y; Zhu Y; Bustin M; Zhang S; Gonzalez FJ; Jiang C
J Clin Invest; 2021 May; 131(9):. PubMed ID: 33938457
[TBL] [Abstract][Full Text] [Related]
11. Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064.
Moscovitz JE; Kong B; Buckley K; Buckley B; Guo GL; Aleksunes LM
Toxicol Appl Pharmacol; 2016 Nov; 310():60-67. PubMed ID: 27609522
[TBL] [Abstract][Full Text] [Related]
12. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
13. Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice.
Qi Y; Jiang C; Cheng J; Krausz KW; Li T; Ferrell JM; Gonzalez FJ; Chiang JY
Biochim Biophys Acta; 2015 Jan; 1851(1):19-29. PubMed ID: 24796972
[TBL] [Abstract][Full Text] [Related]
14. Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation.
Sheng L; Jena PK; Liu HX; Kalanetra KM; Gonzalez FJ; French SW; Krishnan VV; Mills DA; Wan YY
Sci Rep; 2017 May; 7(1):1748. PubMed ID: 28496104
[TBL] [Abstract][Full Text] [Related]
15. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Cipriani S; Mencarelli A; Palladino G; Fiorucci S
J Lipid Res; 2010 Apr; 51(4):771-84. PubMed ID: 19783811
[TBL] [Abstract][Full Text] [Related]
16. Role of FXR in β-cells of lean and obese mice.
Schittenhelm B; Wagner R; Kähny V; Peter A; Krippeit-Drews P; Düfer M; Drews G
Endocrinology; 2015 Apr; 156(4):1263-71. PubMed ID: 25599407
[TBL] [Abstract][Full Text] [Related]
17. Microbiota-induced obesity requires farnesoid X receptor.
Parséus A; Sommer N; Sommer F; Caesar R; Molinaro A; Ståhlman M; Greiner TU; Perkins R; Bäckhed F
Gut; 2017 Mar; 66(3):429-437. PubMed ID: 26740296
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
[TBL] [Abstract][Full Text] [Related]
19. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
[TBL] [Abstract][Full Text] [Related]
20. Defective FXR-SHP Regulation in Obesity Aberrantly Increases
Seok S; Sun H; Kim YC; Kemper B; Kemper JK
Diabetes; 2021 Mar; 70(3):733-744. PubMed ID: 33328206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
